Skip to Content
Merck
  • [Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].

[Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].

Eksperimental'naia i klinicheskaia farmakologiia (2013-03-07)
E B Belonovskaia, E E Naruta, O Ia Lukivskaia, V Z Abakumov, V U Buko
ABSTRACT

We have studied the prophylactic effect of new derivatives of ursodeoxycholic acid (UDCA), including UDCA-N-acetylcysteine, UDCA-L-acetylcysteine, and nor-UDCA (in doses equivalent to 40 mg/kg of UDCA) on the development of experimental alcoholic steatohepatitis induced by the Lieber-DeCarli liquid ethanol-containing diet. Results demonstrated that most of the investigated compounds produced a hepatoprotective effect, improving biochemical tests and liver morphology, as manifested by decreasing steatosis intensity, activity of alkaline phosphatase and gamma-glutamyltranspeptidase, triglyceride level in blood serum and liver, and TNF alpha content. However, nor-UDCA was most effective as compared to UDCA in preventing the accumulation of triglycerides in the liver.

MATERIALS
Product Number
Brand
Product Description

Ursodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
γ-Glutamyl Transferase, ERM®, certified reference material
Sigma-Aldrich
Ursodeoxycholic acid, ≥99%
Sigma-Aldrich
γ-Glutamyltranspeptidase from equine kidney, Type VI, 5-12 units/mg solid
Sigma-Aldrich
γ-Glutamyltranspeptidase from porcine kidney, Type IV, 2.0-6.0 units/mg solid
Ursodeoxycholic acid for system suitability, European Pharmacopoeia (EP) Reference Standard